SynthesisMedicine2016
Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Synthesis in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05790356 (Fecal Microbial Transplantation for Rheumatoid Arthritis Trial), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbial Transplantation for Rheumatoid Arthritis Trial
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Fecal Microbiota Transplantation (FMT) and Clinical Outcomes Among Inflammatory Bowel Disease (IBD) Patients: An Umbrella Review.Digestive diseases and sciences · 2025Pooled it
- Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2018Pooled it
- Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.BioMed research international · 2018Pooled it
- Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.Medicine · 2017Trial
- Protocol for a pilot feasibility randomised controlled trial of fecal microbiota transplantation for adolescent anorexia nervosa.BMJ open · 2026Article
- Balancing safety and effectiveness: parent preferences for fecal microbiota transplant and established therapies in pediatric inflammatory bowel disease-results of a multicenter Canadian study.Crohn's & colitis 360 · 2026Article
- A narrative review on fecal microbiota transplantation routes in ulcerative colitis: identifying the optimal approach across key parameters.Annals of medicine and surgery (2012) · 2025Review
- Efficacy of different modalities of faecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis.Therapeutic advances in gastroenterology · 2025Article
- Microbiota Therapy in Inflammatory Bowel Disease.Visceral medicine · 2024Review
- Review
- Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Review
- Current Trends and Challenges of Fecal Microbiota Transplantation-An Easy Method That Works for All?Biomedicines · 2022Review
- Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.World journal of gastroenterology · 2018Review
- The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2018Review
- Faecal microbiota transplantation: a regulatory hurdle?BMC gastroenterology · 2017Review
- Management of inflammatory bowel disease withWorld journal of gastroenterology · 2017Review
- Recent advances in understanding and managing Crohn's disease.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Variation in clinical evidence has prevented the adoption of fecal microbiota transplantation (FMT) in patients with ulcerative colitis (UC). We aimed to conduct a systematic review and meta-analysis to determine the efficacy and safety of FMT in UC.A systematic literature search was performed in 5 electronic databases from inception through September 2015. Inclusion criteria were reports of FMT in patients with UC. Studies were excluded if they did not report clinical outcomes or included patients with infections. Clinical remission (CR) was defined as the primary outcome.Eleven studies (2 randomized controlled trials (RCTs), 1 open-label case-control study, and 8 cohort studies) with a total of 133 UC patients were included in the analysis. In 11 studies (including 8 noncontrol cohort studies and the treatment arms of 3 clinical control trials), the pooled proportion of patients who achieved CR was 30.4% (95% CI 22.6-39.4%), with a low risk of heterogeneity (Cochran Q test, P = 0.139; I = 33%). A subgroup analysis suggested that no difference in CR was detected between upper gastrointestinal delivery versus lower gastrointestinal delivery. Furthermore, subgroup analysis revealed that there was no difference in CR between single infusion versus multiple infusions (>1) of FMT. All studies reported mild adverse events.FMT is potentially useful in UC disease management but better-designed RCTs are still required to confirm our findings before wide adoption of FMT is suggested. Additionally, basic guidelines are needed imminently to identify the right patient population and to standardize the process of FMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.